Serotonergic antidepressants in COPD: beneficial or harmful?

Abebaw Mengistu Yohannes

Source: Eur Respir J, 52 (1) 1801095; 10.1183/13993003.01095-2018

Journal Issue: July

Disease area: Airway diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Abebaw Mengistu Yohannes. Serotonergic antidepressants in COPD: beneficial or harmful?. Eur Respir J, 52 (1) 1801095; 10.1183/13993003.01095-2018

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Are bronchodilator drugs really useful in COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 94s Year: 2001
Detrimental effects of Beta-blockers in COPD Source: Annual Congress 2009 - Beta-blockers may now be beneficial in asthma and COPD Year: 2009
Serotonergic antidepressant use and morbidity and mortality among older adults with COPD Source: Eur Respir J, 52 (1) 1800475; 10.1183/13993003.00475-2018 Year: 2018
Efficacy of antiepileptic drugs diphenine and carbamazepine in pharmacotherapy of children with bronchial asthma: is asthma a neurogenic inflammatory disease? Source: Eur Respir J 2006; 28: Suppl. 50, 204s Year: 2006
Reducing cholinergic constriction: the major reversible mechanism in COPD Source: Eur Respir Rev 2006; 15: 32-36 Year: 2006
Opioid use, perhaps a harbinger of worsening COPD? Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases Year: 2020
Is the coprescription of Beta-blockers and Beta2-agonists justified in patients with coexisting COPD and CHF? Source: Annual Congress 2009 - Beta-blockers may now be beneficial in asthma and COPD Year: 2009
T-cells in COPD: harmful or protective? Source: Annual Congress 2012 - ERS COPD Research Award Ceremony (supported by Boehringer Ingelheim) followed by the Hot Topic "It takes two to tango: innate and adaptive immunity in COPD" Year: 2012
Pharmacological actions of statins: potential utility in COPD Source: Eur Respir Rev 2009; 18: 222-232 Year: 2009
Efficacy of monotherapy with anticonvulsive drugs topiramate and carbamazepine in bronchial asthma: is asthma a neurological disease? Source: Eur Respir J 2004; 24: Suppl. 48, 130s Year: 2004
Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma? Source: Eur Respir Rev 2015; 25: 54-64 Year: 2016
Is it safe to prescribe benzodiazepines or opioids for dyspnoea in interstitial lung disease? Source: Breathe, 15 (2) 137; 10.1183/20734735.0015-2019 Year: 2019
Targeting neuropetides: from antiemetics to bronchodilators? Source: Annual Congress 2012 - ERS Romain Pauwels Research Award Ceremony (supported by GlaxoSmithKline) followed by the Hot Topic "The nerves are back!" Year: 2012
Targeting the detrimental effects of sleep disturbances in OSA: CPAP and what else? Source: Research seminar - Targeting the detrimental effects of sleep disturbances and disorders – towards personalized treatment in respiratory diseases Year: 2019
Do long-acting β2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma? Source: Eur Respir J 2001; 17: 1059-1061 Year: 2001
Adverse respiratory effects of opioids for chronic breathlessness: to what extent can we learn lessons from chronic pain? Source: Eur Respir J, 52 (1) 1800882; 10.1183/13993003.00882-2018 Year: 2018
Initial anticholinergic therapy COPD Source: Eur Respir J 2006; 28: Suppl. 50, 29s Year: 2006
Next generation of anti-inflammatory therapy for COPD? Source: Eur Respir J, 50 (4) 1702084; 10.1183/13993003.02084-2017 Year: 2017